1. Home
  2. ARCT vs MLYS Comparison

ARCT vs MLYS Comparison

Compare ARCT & MLYS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Arcturus Therapeutics Holdings Inc.

ARCT

Arcturus Therapeutics Holdings Inc.

HOLD

Current Price

$6.87

Market Cap

194.1M

Sector

Health Care

ML Signal

HOLD

Logo Mineralys Therapeutics Inc.

MLYS

Mineralys Therapeutics Inc.

HOLD

Current Price

$35.11

Market Cap

3.1B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ARCT
MLYS
Founded
2013
2019
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
194.1M
3.1B
IPO Year
N/A
2023

Fundamental Metrics

Financial Performance
Metric
ARCT
MLYS
Price
$6.87
$35.11
Analyst Decision
Buy
Strong Buy
Analyst Count
11
7
Target Price
$38.44
$47.33
AVG Volume (30 Days)
627.7K
1.5M
Earning Date
11-10-2025
02-11-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$97,601,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$5.85
$8.24
52 Week High
$24.17
$47.65

Technical Indicators

Market Signals
Indicator
ARCT
MLYS
Relative Strength Index (RSI) 47.68 36.49
Support Level $6.02 $34.21
Resistance Level $6.75 $36.61
Average True Range (ATR) 0.30 1.49
MACD 0.16 -0.02
Stochastic Oscillator 69.87 24.58

Price Performance

Historical Comparison
ARCT
MLYS

About ARCT Arcturus Therapeutics Holdings Inc.

Arcturus Therapeutics Holdings Inc is an RNA medicines company focused on the development of infectious disease vaccines and opportunities within liver and respiratory rare diseases. It operates in one business segment, which includes all activities related to the discovery, development, and commercialization of messenger RNA medicines. The company's pipeline includes LUNAR-OTC and LUNAR-CF. Its Vaccine candidates include LUNAR-FLU, KOSTAIVE XBB.1.5, KOSTAIVE, and Others.

About MLYS Mineralys Therapeutics Inc.

Mineralys Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone. The company's product candidate, lorundrostat, is a proprietary, orally administered, selective aldosterone synthase inhibitor, that is initially developed for the treatment of patients with uncontrolled hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking two or more lines of antihypertensive medication or resistant hypertension, typically including a diuretic.

Share on Social Networks: